ONL Therapeutics   Report issue

For profit Phase 2
Founded: Ann Arbor MI United States (2011)

Organization Overview

First Clinical Trial
2019
NCT03780972
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ONL Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (1)

onl1204 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dissociative Disorders (Phase 1)

Retinal Detachment (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 1